Oral testosterone undecanoate, LPCN 1021 + Topical testosterone gel 1.62 %
Phase 3Completed 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Male Hypogonadism
Conditions
Male Hypogonadism
Trial Timeline
Feb 1, 2014 → May 1, 2015
NCT ID
NCT02081300About Oral testosterone undecanoate, LPCN 1021 + Topical testosterone gel 1.62 %
Oral testosterone undecanoate, LPCN 1021 + Topical testosterone gel 1.62 % is a phase 3 stage product being developed by Lipocine for Male Hypogonadism. The current trial status is completed. This product is registered under clinical trial identifier NCT02081300. Target conditions include Male Hypogonadism.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02081300 | Phase 3 | Completed |
Competing Products
20 competing products in Male Hypogonadism
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ENZ215 + EU Sourced Prolia + US Sourced Prolia | Alkem Laboratories | Phase 1 | 33 |
| Fulvestrant + Abemaciclib | Eli Lilly | Phase 2 | 52 |
| Gemcitabine + liposomal doxorubicin | Eli Lilly | Phase 3 | 77 |
| [14C]-LY3549492 + LY3549492 + [14C]-LY3549492 | Eli Lilly | Phase 1 | 33 |
| CT-P41 + EU-approved Prolia | Celltrion | Phase 1 | 33 |
| CT-P55 + US-licensed Cosentyx + EU-approved Cosentyx | Celltrion | Phase 1 | 33 |
| CT-P52 | Celltrion | Phase 1 | 33 |
| CT-P43 + CT-P43 | Celltrion | Phase 1 | 33 |
| Telmisartan + Amlodipine + Rosuvastatin | Yuhan | Phase 1 | 33 |
| ASP3325 + Placebo | Astellas Pharma | Phase 1 | 33 |
| TRK-100STP | Astellas Pharma | Phase 1 | 33 |
| Ensitrelvir | Shionogi | Phase 1 | 33 |
| E6011 + E6011 Matching Placebo | Eisai | Phase 1 | 33 |
| E6130 + Placebo | Eisai | Phase 1 | 33 |
| Eribulin Injection [Halaven] + Paclitaxel injection | Eisai | Approved | 85 |
| E3112 | Eisai | Phase 1 | 33 |
| E2022 Tape Formulation | Eisai | Phase 1 | 33 |
| Placebo + E3112 | Eisai | Phase 1 | 33 |
| [14C]-E6007 | Eisai | Phase 1 | 33 |
| E2022 + E2022 + E2022 + E2022 + E2022 | Eisai | Phase 1 | 33 |